Sonova refines its analyst picture, shares tracked on SIX Swiss Exchange
Published on 06/25/2026 at 15:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-25, 15:35.
Sonova Holding AG (CH0012549785) remains under close scrutiny from analysts after its full-year 2025/26 results in May, with the shares trading on the SIX Swiss Exchange under the ticker SOON as one of the larger names in the European hearing-care sector. The current assessment spans cautious to constructive views, anchored by recent research from UBS and Bernstein.
What recent notes indicate
On 21 May 2026 UBS lowered its price target on Sonova while maintaining a neutral stance, signaling a more cautious view on upside after the recent results according to a MarketScreener summary of UBS research. The adjustment followed Sonova’s publication of its full-year figures and outlook earlier in the month.
Just days earlier, on 19 May 2026, Bernstein reiterated its Outperform rating and described Sonova’s earnings as a beat with innovation momentum intact, underscoring confidence in the company’s product pipeline and execution in hearing instruments and cochlear implants as captured in the same analyst roundup. This contrast between UBS and Bernstein highlights a split between more valuation-focused and more growth-focused perspectives.
How consensus shapes expectations
Across the broader analyst community, Sonova is typically covered by a double-digit number of banks and brokers, with a mix of Buy, Hold and occasional Sell ratings according to aggregated consensus data on platforms such as MarketScreener, which list Sonova among European medtech peers like Demant and GN Store Nord in the hearing-aid space. The average target price described there implies moderate upside from recent trading levels, though individual estimates differ materially between cautious and optimistic houses as seen in the spread of targets in the same consensus overview.
The May 18, 2026 earnings call, also documented in that analyst compilation, provided detail on Sonova’s financial year, including revenue growth, margin development and the company’s guidance framework, which together form the numerical basis for current valuation models. For many analysts, execution on cost control and continued demand for premium hearing instruments are key sensitivity points in those models.
All news and analysis on the Sonova shares
Price data, regulatory disclosures and further analyst commentary on Sonova can be found bundled in the dedicated topic area and on the company’s investor relations pages.
How Sonova earns its money
Sonova generates the bulk of its revenue with hearing instruments and related services, selling branded devices such as Phonak hearing aids and advanced cochlear implant systems worldwide through audiologists, clinics and specialist retailers. The company also operates retail networks in selected markets, adding recurring service income to its product sales.
Where the stock trades today
The Sonova shares (CH0012549785) trade on the SIX Swiss Exchange in Zurich under the ticker SOON; the latest available quotes on exchange data providers place the stock in the mid-cap range of Swiss equities, with prices reported in Swiss francs.
Key data on the Sonova shares
- Company: Sonova Holding AG
- ISIN: CH0012549785
- WKN: 893484
- Ticker: SOON
- Trading venue: SIX Swiss Exchange
- Price (as of latest available quote): [current] CHF
- Market cap: [current] CHF (as of latest available data)
- Sector / industry: Health Care / Medical Devices & Equipment
- Index membership: SMI MID (SMIM)
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. Historical performance is not a reliable indicator of future results.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
